|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
An increase of 0.1 in NDVI corresponded to a reduction in SBP of 1.39 mmHg (95% CI: 1.86, -0.93) and lower odds of hypertension (OR = 0.76, 95% CI: 0.69, 0.82).
|
31672364 |
2020 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Participants with hypertension but without diabetes (N = 1167) were randomized to an SBP target below 120 mm Hg (intensive treatment) vs a target below 140 mm Hg (standard treatment).
|
31840813 |
2020 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
Stage 2 hypertension (SBP/DBP ≥ 140/90 mmHg) showed significant associations with cardiovascular disease and all-cause mortality, while elevated blood pressure (SBP 120-129 mmHg and DBP < 80 mmHg) showed null associations.
|
31288541 |
2020 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
Patients with high Hcy and MTHFR 667CC, as well as those with low Hcy and 667CT+TT, showed lower odds of uncontrolled SBP (MTHFR 667CC+ high Hcy: OR: 0.338, 95% CI: 0.115-0.996, Pcombined = 0.049; MTHFR 667CT/TT+ low Hcy: OR: 0.421, 95% CI: 0.193-0.921, Pcombined = 0.030) compared to patients with low Hcy and MTHFR 667CC.<b>Conclusions</b>: Serum Hcy status and Hcy metabolism gene polymorphisms (MTHFR C667T and MTRR A66G) may have synergistic effects on the prevalence of HTN and dyslipidemia.
|
30786773 |
2020 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
We used inverse variance weighting (IVW) to assess the relation of HbA1c with risk of hypertension (defined using the American College of Cardiology/American Heart Association 2017 guidelines), and SBP and DBP.
|
31386636 |
2020 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
To obtain inter-arm differences of SBP (the absolute difference of right and left arm) and ankle-brachial index, bilateral blood pressures were measured simultaneously at the four limbs using an automated oscillometric device in patients with treated hypertension (n = 234) and in normotensive subjects (n = 40).
|
31714348 |
2020 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
One-year hypertension remission and SBP and DBP pressure change at 1 and 5 years after both surgical techniques were also evaluated.
|
31633582 |
2020 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
Epidemiological studies reported an inconsistent association between stage 1 hypertension (SBP 130-139 mmHg or DBP 80-89 mmHg) defined by the 2017 American College of Cardiology/American Heart Association hypertension guidelines and cardiovascular disease (CVD) events.
|
31790053 |
2020 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
For subjects (n = 50) who exhibited uncontrolled morning hypertension (home systolic blood pressure [SBP]≥125 mmHg) at the end of study period I (at 8 weeks), nifedipine CR (20-40 mg) was added at bedtime, and rivaroxaban administration was continued an additional 8 weeks.
|
31542950 |
2020 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Hypertension was defined as SBP at least 130 mmHg or DBP at least 80 mmHg, taking antihypertensive medicine or self-report.
|
31356404 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
We assessed the role of SBP VVV on the development of CKD in patients with type 2 diabetes (T2D) and hypertension in real life.
|
30817462 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Further logistic analysis indicated that the irisin level was positively correlated with SBP and an independent predictor for hypertension after adjustment.
|
31133682 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
These trials - SPYRAL OFF-MED, RADIANCE SOLO and SPYRAL ON-MED - using newer technologies, demonstrate a 5-10 mmHg incremental reduction in ambulatory SBP from RDN against sham-control, in patients with mild-to-moderate hypertension taking 0-3 drugs.
|
31268917 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
Prespecified analyses of the Enhanced Control of Hypertension and Thrombolysis Stroke Study for patients enrolled in both arms: (i) low-dose (0.6 mg/kg body weight) or standard-dose (0.9 mg/kg) alteplase and (ii) intensive (target systolic BP [SBP] 130-140 mm Hg) or guideline-recommended (target SBP <180 mm Hg) BP management.
|
31812956 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
This randomized-cross-over study included 38 patients (age: 60.4 ± 11.1 years, male: 65.8%) with intradialytic hypertension (intradialytic-SBP increase ≥ 10 mmHg at ≥4 over 6 consecutive sessions).
|
30622317 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Childhood hypertension and elevated blood pressure were defined as SBP and/or DBP ≥95th and ≥90th age- and gender-specific percentile, respectively.
|
31826379 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
In a univariate logistic regression analysis hypertension and clinic SBP were not associated with revealed symptoms.
|
31157741 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
We analyzed OH measurements from the Action to Control Cardiovascular Risk in Diabetes BP trial, which evaluated two blood pressure (BP) goals (systolic BP [SBP] < 120 mm Hg vs. SBP < 140 mm Hg) and incident CVD among adults with diabetes and hypertension.
|
30715100 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Hypertension was measured as SBP at least 140 mmHg or DBP at least 90 mmHg.Random-effects meta-analysis was used.
|
31166251 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Systolic and diastolic blood pressure (SBP and DBP), and pulse pressure (PP), low-density lipoprotein cholesterol and triglyceride levels, RRI, RPI, kidney length, IVSd, PWd, and LVMI were significantly higher in patients with HT (both p < 0.05).
|
30285504 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Recent hypertension guidelines endorsed SBP targets below 130 or lower for all or some hypertensive patients to reduce cardiovascular events (CVEs) more than the prior SBP target less than 140.
|
30624370 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
The results of subgroups showed that, there were statistically significant differences in the age of >50 years subgroup on ΔSBP [WMD = -2.32, 95% CI (-4.39, -0.25) P = .03]; there were statistically significant differences in the hypertension subgroup on ΔSBP [WMD = -6.58, 95% CI (-8.72, -4.44) P <.00001]; there were statistically significant differences in the hypertension subgroup on ΔDBP [WMD = -3.07, 95% CI (-4.66, -1.48) P = .0002]; there were statistically significant differences in the body mass index (BMI) >30 subgroup on ΔSBP [WMD = -3.51, 95% CI (-5.96, -1.07) P = .005].
|
31083159 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
AlteredExpression |
BEFREE |
The PLR had an inverse relationship with the degree of hypertension; SBP p value of 0.0001, while DBP was p = 0.0001.
|
30835575 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
The mean SBP greater than 120 mmHg had higher prevalence of cardiovascular risk factors, such as diabetes (38.4 vs. 27.2%, P = 0.001), hypertension (58.8 vs. 32.4%, P < 0.001), and chronic kidney disease (3.3 vs. 1.0%, P = 0.043) than mean SBP 120 mmHg or less.
|
31045965 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Our aim was to assess the impact of cumulative SBP and SAEs on intensive hypertension treatment efficacy in the Systolic Blood Pressure Intervention Trial (SPRINT) population during follow-up.
|
30444838 |
2019 |